ArteraAI

We're happy to announce the #ArteraAI Prostate Test is the First-and-Only Predictive Test for Therapy Personalization in the 2024 @NCCN Guidelines for #ProstateCancer underscoring the importance of incorporating innovative tools for personalized treatment: bit.ly/48G5FBI

The team is headed to the Advanced Urology Institute 2025 Conference next week! We look forward to connecting with leaders in #Urology and sharing more about how #ArteraAI is shaping the future of #prostatecancer care. Reach out to us to set up a meeting. @AdvancedUrology

It's a treat to hear Dr. Mack Roach speak at #NMA2025 about his research on #ArteraAI and its algorithmic fairness. He's been at the forefront of advancing #prostatecancer care and we're honored to collaborate with him. Special thanks to @CurtilandD for organizing the session.

Not all risk is equal—and not all patients need the same treatment. The ArteraAI Prostate Test supports decisions across all NCCN risk groups, with 10-year risk of distant metastasis and prostate cancer mortality reported. Now available in all 50 states: artera.ai/for-clinicians

At #ASCO25, Prof. Nicholas James spoke with @urotoday about how an Artera's AI model helped identify high-risk patients (STAMPEDE) who benefited most from treatment intensification. Watch: heyor.ca/BLXIL5 #ArteraAI #ProstateCancer

ICYMI: Artera’s DIRECT-AI registry is tracking how the ArteraAI Prostate Test impacts treatment decisions and outcomes for localized prostate cancer. This study advances personalized care by monitoring metastasis, survival & treatment effectiveness: urologytimes.com/view/study-to-…

We're headed to the @NationalMedAssn annual meeting next week! Reach out to set up a meeting with our Marketing Director, Michael Chang, to learn more about how #ArteraAI is making a difference in #prostatecancer care.

We’re proud to share that the @US_FDA has granted Breakthrough Device Designation to ArteraAI Prostate—the first and only AI-powered risk stratification tool for prostate cancer to receive this status. A step forward for personalized, risk-based care: mpo-mag.com/breaking-news/…

At #ASCO25, our CMO Dr. Tim Showalter spoke with @urotoday about how our #MMAI test predicts #prostatecancer distant metastasis rates and treatment response. Watch the full interview: heyor.ca/HEU5os #ArteraAI #ProstateCancer #PrecisionMedicine

How does Artera’s MMAI architecture work? Our multimodal AI model analyzes both a patient’s biopsy image and their clinical data to predict therapeutic benefit—something conventional tools can’t do alone. 🔬 Watch the breakdown to see how it works:

Looking for Software Engineers to join @arteraAI 's platform engineering team. You'll be responsible for owning the AWS compute infrastructure that powers ArteraAI's cancer therapy personalization tests across multiple countries and delivery platforms! lnkd.in/eGhRyAMY

That’s a wrap on #ABSBrachy2025 in Nashville! It was great to connect with the brachytherapy community and sharing how Artera is advancing AI in #prostatecancer care. Until next time! 👋

Prof. Nick James of @ICR_London joins The @Uromigos Podcast to discuss #ArteraAI Prostate Test results from #ASCO25, showing how AI can predict which high-risk patients benefit from adding #abiraterone to ADT. 🎧 Listen: guoncologynow.com/podcast/episod…

Did you know: The ArteraAI Prostate Test provides therapy-relevant insights across the spectrum of localized prostate cancer—guiding decisions from active surveillance to short-term ADT to adjunctive abiraterone therapy. Learn more: artera.ai

Want to hear from current #ArteraAI Prostate Test users Drs. Nicolas Zouain and Kenneth Nepple on how to utilize the test results to inform clinical decision making? Watch the recording of our latest webinar: heyor.ca/3XAKo7 #prostatecancer #precisionmedicine

Multimodal AI test predicts #ProstateCancer metastasis and treatment response. @TimShowalter1 @arteraAI joins @l_ballas @CedarsSinai discussing how ArteraAI analyzes H&E-stained biopsy slides using computer vision combined with clinical factors to generate personalized risk…

We are excited to be at BAUS 2025 next week in Manchester, June 16–18! Come visit Diagnexia & @arteraAI at our joint booth to see the new ArteraAI Prostate Biopsy Assay—our first UK launch of this AI-powered, multimodal risk tool for localized prostate cancer. Come chat with…

Artera is proud to announce the launch of DIRECT-AI, a first-of-its-kind study assessing the real-world impact of the ArteraAI Prostate Test on treatment decisions and long-term outcomes for localized prostate cancer patients: urotoday.com/recent-abstrac…

Mental well-being is a critical, often overlooked part of the cancer journey. In @PsychToday, Dr. Tim Showalter explores how AI-powered tools like the ArteraAI Prostate Test can reduce anxiety by bringing clarity to care: psychologytoday.com/us/blog/well-b… #MentalHealthAwareness #MHAM

We’re proud to wear blue in support of #MensHealthWeek and #WearBlueDay. With prostate cancer ranking as the second most common cancer in U.S. men according to @AmericanCancer, it’s a powerful reminder of the value of early detection, awareness, and personalized care.

We’re headed to NYC this June for the @nyulangone Therapeutic Radiology Spring Symposium! Excited to connect and share how Artera is advancing AI-driven tools in prostate cancer care. #RadiationOncology #ProstateCancer #ArteraOnTheGo